NCT01526941View on ClinicalTrials.gov

Comparison of Single Dose and Steady State Pharmacodynamics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

May 31, 2001

Primary Completion Date

July 31, 2001

Study Completion Date

July 31, 2001

Conditions
DiabetesDiabetes Mellitus, Type 1
Interventions
DRUG

biphasic insulin aspart 30

Dose individually adjusted. Administered subcutaneously (s.c., under the skin) three times a day for 1 week in each treatment period. A wash-out period of 2-6 weeks will take place between treatment periods

DRUG

biphasic insulin aspart 70

Dose individually adjusted. Administered subcutaneously (s.c., under the skin) three times a day for 1 week in each treatment period. A wash-out period of 2-6 weeks will take place between treatment periods

Trial Locations (1)

41460

Novo Nordisk Investigational Site, Neuss

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT01526941 - Comparison of Single Dose and Steady State Pharmacodynamics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 Diabetes | Biotech Hunter | Biotech Hunter